免疫治療藥物市場 - 按藥物類型、應用、給藥途徑、配銷通路- 全球預測

Immunotherapy Drugs Market - By Drug Type, Application, Route of Administration, Distribution Channel - Global Forecast

出版日期: 2024年05月31日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

受領先製藥公司不斷增加的撥款和許可的影響，全球免疫療法藥物市場 2024 年至 2032 年間的複合年成長率將達到 10.4%。這些金融投資和監管批准正在加速創新免疫療法的開發和可用性。政府機構和私人組織的資助正在促進先進研究，使公司能夠探索新的治療目標並完善治療方案。同時，監管機構越來越快地批准有前景的免疫療法藥物，並認知到它們徹底改變癌症治療和其他自體免疫疾病的潛力。

例如，2022 年 7 月，美國食品藥物管理局 (FDA) 延長了羅斯威爾公園綜合癌症中心開發的腦癌免疫療法 SurVaxM 的孤兒藥資格。

這些支持措施正在增加臨床試驗機會並加速新療法的市場進入。隨著領先公司獲得更多資助並成功應對監管環境，免疫療法藥物的管道不斷擴大，滿足了對有效、有針對性的治療日益成長的需求。財政支持和監管便利之間的協同作用正在推動市場成長，將免疫療法定位為未來醫療的關鍵組成部分。

整個免疫治療藥物產業根據藥物類型、應用、給藥途徑、配銷通路和地區進行分類。

根據藥物類型，疫苗領域的免疫療法藥物市場收入從2024 年到2032 年將實現令人稱讚的複合年成長率。。隨著正在進行的研究和臨床試驗證明其具有提高治療效果和患者預後的潛力，癌症疫苗正在獲得越來越多的關注。人們日益關注免疫療法作為可行的治療選擇，再加上預防措施和個人化方法的推動，正在推動市場成長。隨著製藥公司投資開發和商業化這些創新疫苗，對免疫療法藥物的需求將大幅上升。

在應用方面，自體免疫疾病領域將在2024年至2032年出現顯著成長。新的希望。隨著研究更多地揭示免疫系統在這些疾病中的作用，免疫療法在控制症狀和改變疾病進展方面變得越來越有效。自體免疫疾病的日益普及以及對有針對性的個人化治療的需求推動了市場的成長。研究和開發的投資進一步加速了新型免疫療法的上市，改善患者的治療效果，並推動市場擴張。

2024年至2032年，歐洲免疫療法藥物市場將呈現顯著的複合年成長率。歐盟的支持性監管環境和創新療法的資助計畫進一步增強了這一需求。此外，患者和醫療保健提供者對免疫療法益處的認知不斷提高，推動了市場擴張。隨著歐洲製藥公司投資研發並合作進行臨床試驗，對尖端免疫療法藥物的需求可能會繼續呈上升趨勢。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Amgen Inc.
AstraZeneca
Bayer AG
Boehringer Ingelheim
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Genmab A/S
GSK plc
Immatics N.V.
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
Sanofi

簡介目錄

Product Code: 9713

Global Immunotherapy Drugs Market will witness 10.4% CAGR between 2024 and 2032, influenced by rising grants and permissions from leading pharmaceutical companies. These financial investments and regulatory approvals are accelerating the development and availability of innovative immunotherapy treatments. Grants from government bodies and private organizations are facilitating advanced research, enabling companies to explore new therapeutic targets and refine treatment protocols. Concurrently, regulatory agencies are increasingly fast-tracking approvals for promising immunotherapy drugs, recognizing their potential to revolutionize cancer treatment and other autoimmune disorders.

For instance, in July 2022, the U.S. Food and Drug Administration (FDA) extended the orphan drug designation for SurVaxM, an immunotherapy for brain cancer developed at Roswell Park Comprehensive Cancer Center.

These supportive measures are enhancing clinical trial opportunities and expediting market entry for novel therapies. As leading companies secure more grants and navigate regulatory landscapes successfully, the pipeline for immunotherapy drugs expands, meeting the growing demand for effective, targeted treatments. This synergy between financial support and regulatory facilitation is driving market growth, positioning immunotherapy as a pivotal component in the future of medical treatments.

The overall Immunotherapy Drugs Industry is classified based on the drug type, application, route of administration, distribution channel, and region.

Based on drug type, the immunotherapy drugs market revenue from the vaccines segment will register a commendable CAGR from 2024 to 2032. These vaccines, designed to stimulate the immune system to target and destroy cancer cells, represent a significant leap forward in personalized medicine. With ongoing research and clinical trials demonstrating their potential to enhance treatment efficacy and patient outcomes, cancer vaccines are gaining traction. The growing focus on immunotherapy as a viable treatment option, combined with the push for preventive measures and personalized approaches, is fueling market growth. As pharmaceutical companies invest in developing and commercializing these innovative vaccines, the demand for immunotherapy drugs will rise substantially.

In terms of application, the auto immune diseases segment will witness appreciable growth from 2024 to 2032. These drugs, which harness the body's immune system to target and modify disease mechanisms, offer new hope for conditions like rheumatoid arthritis, multiple sclerosis, and lupus. As research uncovers more about the immune system's role in these disorders, immunotherapies are becoming increasingly effective in managing symptoms and altering disease progression. The growing prevalence of autoimmune diseases and the need for targeted, personalized treatments drive market growth. Investments in research and development are further accelerating the availability of novel immunotherapies, enhancing patient outcomes, and fueling market expansion.

Europe immunotherapy drugs market will exhibit a notable CAGR from 2024 to 2032. European countries are increasingly adopting immunotherapies due to their promising results in targeting specific cancer cells and improving patient outcomes. The European Union's supportive regulatory environment and funding initiatives for innovative therapies further bolster this demand. In addition, rising awareness among patients and healthcare providers about the benefits of immunotherapy fuels market expansion. As European pharmaceutical companies invest in research and development and collaborate on clinical trials, the demand for cutting-edge immunotherapy drugs could continue its upward trajectory.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of chronic diseases
  - 3.2.1.2 Growing adoption of combination therapies
  - 3.2.1.3 Technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Monoclonal antibodies
5.3 Vaccines
5.4 Check point inhibitor
5.5 Interferons alpha & beta
5.6 Interleukins
5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Cancer
6.3 Autoimmune diseases
6.4 Infectious diseases
6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Intravenous
7.3 Subcutaneous
7.4 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacy
8.3 Brick and mortar
8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa